anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Patients will perform deep breaths (3 sets of 10 repetitions), once a day, for 30 minutes until 7th postoperative day. Non invasive ventilation will be installed after orotracheal extubation for 30 to 60 minutes.Early mobilization protocol consist of upper and lower (cycle ergometer) limb exercises, chair transfer, deambulation for 10 to 20 minutes, step exercise (six times).
Hepatitis C screening is based on a blood test, in particular the Elisa test, which looks for anti-HCV antibodies. In the case of positive C viral serology, the search for the C virus from a blood test makes it possible to detect the genome (RNA) of the virus, which is thus directly detected by a so-called "PCR" technique. Although screening activity is important in France, it remains insufficient. In December 2016, HAS concluded that risk-based targeted screening has limitations and contributes to the persistence of a hidden epidemic of viral C infection. It is estimated that 75,000 people are unaware of being carriers of the hepatitis C virus. However, there is safe, effective and well-tolerated treatment. With duration of 8 to 12 weeks it allows a healing of HCV in more than 95% of subjects. AFEF recommendations aim to achieve viral elimination C (as early as 2025). This elimination is defined as a 90% decrease in new infections associated with a 65% reduction in HCV mortality. OMS has planned this target for 2030. To achieve this goal, a number of measures are gradually being implemented focusing on universal treatment and universal screening. The hospital may be a place where systematic screening is interesting. In 2017, the prevalence of anti-HCV positive antibodies in the facility, apart from the Hepato-Gastroenterology service, was 1.7%, more than twice the estimated prevalence in our general population. These data give a rationale for the realization of this study.
PURPOSE:To provide the titled composition composed of a stock liquid and a propellant each having specific compound and composition, and having improved dispersibility of a water-soluble component and a water-insoluble component, quick-drying property and bubble-bursting sound, etc., by using ethanol and/or isopropyl alcohol. CONSTITUTION:100pts.wt. of an aqueous solution containing 3-60wt% ethanol and/or isopropyl alcohol is compounded with 0.01-10pts.wt. of a surfactant and/or 0.1-50pts.wt. of powder and 0.1-50pts.wt. of an active component of hair-tonic to obtain a stock liquid. The titled composition is produced by compounding 2-30pts.wt. of the stock liquid with 70-98pts.wt. of a propellant composed mainly of dichlorotetrafluoroethane. The composition forms foam by spraying in the form of bubbles or mist and produces cracking sound by the bursting of the bubbles. The water-soluble component and the water-insoluble component can be uniformly dispersed in the above composition by the aid of the above alcohol. The composition produces large sound by the bursting of bubbles, has quick-drying property, is free from sticky feeling and dripping of liquid and gives refreshing feeling to the skin.
Cystic fibrosis (CF) is the most common inherited life-limiting disease in North European people affecting 90,000 people worldwide with about 45,000 registered in the Patient Registry of the European Cystic Fibrosis Society (ECFS). Progressive lung damage caused by recurrent infection and persistent inflammation is the major determinant of survival with a median age of death at 29 years. Approximately 60% of CF patients are infected with A. fumigatus, a ubiquitous environmental fungus,and its presence is associated with accelerated lung function decline. Half of the patients infected with Aspergillus are \<18 years of age. Evidence to guide clinical management of CF-related Aspergillus disease is lacking. A recent survey showed considerable variability in clinical practice among CF consultants. Two-thirds would treat Aspergillus colonization in patients with CF and two-thirds would use an azole antifungal in addition to steroids in the first line treatment of CF-related allergic bronchopulmonary aspergillosis (ABPA). The results of this survey underscore the limited evidence available to guide management of Aspergillus infection in CF.

Posaconazole, being one of the 4 licensed triazole antifungals with good efficacy against Aspergillus species has been chosen as the study drug as it has a better tolerability compared to itraconazole, less toxicity and drug-drug interactions compared to voriconazole and can be administered once daily. Posaconazole is licensed in Europe for the prevention of invasive aspergillus in adult neutropenic patient populations and as salvage therapy for invasive aspergillosis. Several studies have reported on the safety and tolerability of the use of posaconazole in children and adolescents with either haematological malignancies, or chronic granulomatous disease, or those undergoing haematopoietic stem cell transplantation. Currently, no dosing algorithm is available to guide posaconazole dosing in children.
A wearable device is disclosed configured to provide and transmit user information. Health-related information that is associated with a user information is received and output to a user. The wearable device can include a display configured to provide a user interface and a sensor senses information associated with biological features, physiological features and/or physical activity of the user, while the device is being worn. A communications subsystem is provided that is configured to communicate with the remote computing device. The wearable device includes a processing subsystem is provided and configured to process the sensed information to provide processed user information. The processed user information is transmitted via the communication subsystem, to the remote computing device, and health-related information associated with the processed user information is received from the remote computing device. The health-related information is provided, via the user interface, on the display.
1393654 Making viral vaccines MERCK & CO INC 11 June 1973 [14 June 1972] 27636/73 Heading A5B [Also in Divisions Bl and C6] In a process for the production of cells and/ or vaccines cells are grown and/or infected with virus in a rotary multiplate propagator which comprises a cylindrical tank 2 and a plurality of plates 19 mounted normally to the axis of the cylindrical tank and rotatable thereabout, the plate and tank diameters being in the ratio 0.8:1 to 0.9:1. Preferably the surface area to volume ratio of the apparatus lies between 5.5:1 and 6.0:1. The tank may be of stainless steel, and the plates of titanium, and typical diameters are 7“ inches and 6 inches or 6 inches and 5.4 inches respectively. Drive to the shaft 20 on which the plates are mounted includes a magnetic coupling 25, 26 and the tank is provided with inlet and outlet connections for supply and egress of air or air/CO 2 mixture, culture medium and product or spent liquor. Coating of the plates with cells is effected with the apparatus placed with its axis vertical and the apparatus may be inverted to ensure coating of both sides of the plates. Cell growth or infection of cells grown on the plates is carried out with the apparatus horizontal, about half full of liquid medium and with the plates rotating e.g. at about 1/5 r.p.m. Reference is made and examples given relating to production of viral vaccines such as mumps, measles, rubella, Marek's, influenza, parainfluenza, varicella, trachoma, and respiratory syncytia and cells such as WI-38, chick embryo and duck embryo cells.
[GB1393654A]
1,186,918. Phenothiazines. LABOBATOIRES TORAUDE. 16 Oct., 1968 [16 Oct., 1967], No. 47043/67. Heading C2C. Compounds of the formula and their acid addition salts, in which X is H or halogen, an alkyl, cycloalkyl, alkoxy, or alkylthio, group, an acyl or blocked acyl group in the form of ethylene ketal, CF 3  or Me 2 NSO 2 , alkyl, alkoxy alkylthio and acyl radicals containing up to 6 C; R is NR 1 R 2  in which each of R 1  and R 2  is H 1-6 C alkyl or NR 1 R 2  is a heterocyclic group containing 5 or 6 atoms; and n is 0, 1 or 2 are prepared by reacting an amidoxime of the formula with an anhydride of a chloroalkanoic acid containing up to 3 C in the presence of an inert organic solvent, cyclizing the product obtained and replacing the halogen atom in the cyclized product by R. Pharmaceutical compositions comprise one or more of the compounds (I) and a carrier therefor. The compounds have psychotropic, analgesic, anti-histaminic and anti-inflammatory action.
hTERT is widely found in breast cancer cells and has a role in tumor growth and development, making it attractive for immunotherapy. Also, recent data suggest that breast cancer is potentially responsive to immunological therapies. In one trial, patients with advanced cancer received a series of hTERT vaccinations and 4 of 7 patients with advanced breast or prostate carcinoma developed hTERT-specific T lymphocytes. Partial tumor regression was observed in 1 patient. In a second trial, 19 HLA A2+ patients with metastatic breast cancer were vaccinated with hTERT 1540 peptide in adjuvant with GM-CSF. 68% of patients exhibited immunological responses with development of CD8+ hTERT-specific T-cells. Overall survival of vaccine responders was signifiantly better than the overall survival on non-responders. In order to expand the number of possible immune responses and to potentially bypass immune tolerance, multiple peptides have been added to the vaccine. In addition, the monoclonal antibody basiliximab is included to decrease the regulatory T cells which prevent the immune system to work against the tumor, and GM-CSF and Prevnar are used to boost the immune system. Subjects will receive a maximum of 28 vaccinations over a 24 months period.
Insertion of abdominal drainage tube to drain intra-abdominal abscess. Normal Saline administered immediately post drain insertion. Normal Saline (10 cc) allowed to dwell for one hour, then allowed to drain into drainage bag.
Daily, 4-week, 5-days per week treatment sessions. The sham coil will generate auditory and somatosensory (vibratory) stimuli identical to the active stimulation.
Deep learning has shown great promise in predicting Atrial Fibrillation using ECG signals and other vital signs. However, a major hurdle lies in the privacy concerns surrounding these datasets, which often contain sensitive patient information. Balancing accurate AFib prediction with robust user privacy remains a critical challenge to address. We suggest Federated Learning , a privacy-preserving machine learning technique, to address this privacy barrier. Our approach makes use of FL by presenting Fed-CL, a advanced method that combines Long Short-Term Memory networks and Convolutional Neural Networks to accurately predict AFib. In addition, the article explores the importance of analysing mean heart rate variability to differentiate between healthy and abnormal heart rhythms. This combined approach within the proposed system aims to equip healthcare professionals with timely alerts and valuable insights. Ultimately, the goal is to facilitate early detection of AFib risk and enable preventive care for susceptible individuals.
Myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) is a debilitating chronic condition that is characterized by unresolved fatigue, post-exertion symptom exacerbation (PESE), cognitive dysfunction, orthostatic intolerance, and other symptoms. ME/CFS lacks established clinical biomarkers and requires further elucidation of disease mechanisms. A growing number of studies demonstrate signs of hematological and cardiovascular pathology in ME/CFS cohorts, including hyperactivated platelets, endothelial dysfunction, vascular dysregulation, and anomalous clotting processes. To build on these findings, and to identify potential biomarkers that can be related to pathophysiology, we measured differences in protein expression in platelet-poor plasma (PPP) samples from 15 ME/CFS study participants and 10 controls not previously infected with SARS-CoV-2, using DIA LC-MS/MS. We identified 24 proteins that are significantly increased in the ME/CFS group compared to the controls, and 21 proteins that are significantly downregulated. Proteins related to clotting processes - thrombospondin-1 (important in platelet activation), platelet factor 4, and protein S - were differentially expressed in the ME/CFS group, suggestive of a dysregulated coagulation system and abnormal endothelial function. Complement machinery was also significantly downregulated, including C9 which forms part of the membrane attack complex. Additionally, we identified a significant upregulation of lactotransferrin, protein S100-A9, and an immunoglobulin variant. The findings from this experiment further implicate the coagulation and immune system in ME/CFS, and bring to attention the pathology of or imposed on the endothelium. This study highlights potential systems and proteins that require further research with regards to their contribution to the pathogenesis of ME/CFS, symptom manifestation, and biomarker potential, and also gives insight into the hematological and cardiovascular risk for ME/CFS individuals affected by diabetes mellitus.
The phase C treatment (2 hours a day, 5/7 days of conventional rehabilitation) is scheduled before phase B (1.5 hours a day, 5/7 days of conventional rehabilitation and 30mn a day, 5/7 days of treatment with the robot). The duration of phase C is randomized between 6 and 11 evaluations (2 to 3.5 weeks).
CD19/CD20 Dual-CAR-T cells are prepared via lentiviral infection. 5 days prior to infusion of CAR-T cells, subjects receive fludarabine at dose 30mg/m2/day and cyclophosphamide treatment at dose 250mg/m2 for 3 days and take a rest for 2 days before infusion.
The invention relates to an original prescription and processing technology for a nourishing wine. The processing technology is different from prior process that medicines and deer penis are mixed and soaked in wine; now, the effective medicines and deer penis are decocted in water; the preparation method is improved, so are the efficacy and quality of the wine. The wine with sweet taste and small medicine smell is suitable for drinking and combines daily drinking and medical care. The arrangement of the medicinal materials in the nourishing wine is as follows (using weight account): deer penis 30-40g, angelica 5-8g, atractylodes macrocephala Koidz 8-12g, ligusticum chuanxiong 7-12g, ginseng 10-20g, prepared rhizome of rehmannia 4-8g, jujube 10-20g and Paeonia lactiflora pallas 4 to 8 g. The nourishing wine utilizes the medicine with deer penis to cure disease and preserve health and combines the health protection and drinking. The wine matched with various Chinese herbal medicines as an enricher and nutrient for the liver and kidney improves blood circulation. The prescription absorbs the essence of traditional prescription; since wine can help purifying turbid blood and promoting blood circulation, medicine can be absorbed more quickly; and the nourishing wine with original prescription also takes consideration of the drinking habits of Chinese people. The wine has the advantages that the wine has rich nutrition and keeps the alcohol flavor; the wine achieves health care function when drinkers are enjoying the wine and is recommendable.
Avid eating behaviours, including greater responsiveness to food cues and emotional over-eating, have been linked to child overweight and obesity. Parental feeding practices are modifiable components of a child's food environment and may be key levers for behaviour change in tailored interventions to support parents of children with avid eating behaviour. However, there is a lack of research examining parents' experiences in this context. This study aimed to explore parents' experiences of feeding children with avid eating behaviour and to understand any challenges experienced in this context. Semi-structured interviews with parents (N = 15) of a preschool child (3-5 years) identified as having an avid eating behaviour profile explored how children's avid eating manifests, the parental feeding practices used to manage avid eating, and the perceived effectiveness of these strategies. Data were analysed using reflexive thematic analysis. Four core themes were generated. Theme one, 'Have they got worms? Children's insatiable hunger', captures parents' interpretation of the complex ways in which avid eating behaviour manifests. Theme two, 'Parenthood as a duty', illustrates how parents' perceived responsibilities shape their feeding practices. Theme three, 'Lifelong habits', captures parents' use of responsive feeding practices to support children's healthy relationship with food. Theme four, 'Picking battles', captures the structure- and coercive-based feeding strategies commonly used to manage children's avid eating. This novel study provides an in-depth understanding of the complex ways that children's avid eating behaviour manifests, and the strategic and creative parental feeding practices used to manage these behaviours. Such findings are valuable for informing the development of future support resources for parents/caregivers to help their children with avid eating behaviours to develop a healthy relationship with food.
The invention discloses a Chinese herbal extract for promoting hair growth and hair blacking and improving dandruff and application thereof. The extract is obtained by extraction of bulk drugs containing ginseng, American ginseng, polygonum multiflorum, rhubarb, dodder and other 57 traditional Chinese medicines. Specifically, each of the traditional Chinese medicines accounts for 0.5wt%-30wt%, and the total composition of the traditional Chinese medicines is 100wt%. The bulk drugs are grinded into powder, the powder is mixed with an organic solvent and water, and then extraction is carried out to obtain the Chinese herbal extract. After extraction, the bulk drugs can release a restoration leading factor, which can promote cell activation and has the function of promoting cell proliferation. Thus, the Chinese herbal extract provided by the invention can be applied to activation of hair follicle cells, activation of melanin cells and other aspects, and can be used as a skin, hair follicle and hair medicine related to the fields, or can be used as an active and auxiliary component of cosmeceutical products associated with the fields.
Individuals are randomly assigned to the treatment group or waitlist control (WLC) group. Individuals will complete the study measures on 2 occasions, 5 weeks apart. In fairness, WLC participants will then be offered the opportunity to participate in the intervention.
Patients with advanced type 2 diabetes like those with type 1 diabetes are at risk for defective glucose counterregulation and hypoglycemia unawareness, the components of hypoglycemia-associated autonomic failure and the resultant vicious cycle of recurrent iatrogenic hypoglycemia. This may explain why iatrogenic hypoglycemia becomes limiting to glycemic control as patients approach the insulin-deficient end of the spectrum of type 2 diabetes. Compared to Neutral Protamin Hagedorn (NPH) insulin glargine is a new long-acting peakless analogue with lower incidence of nocturnal hypoglycemia having the potential to decrease the frequency of hypoglycemia of insulin therapy. Modern type 2 diabetes therapy guidelines recommend insulin for an increasing population of patients. There is no doubt that type 2 diabetic patients suffer from hypoglycemia under insulin therapy, however it is not clear whether the extensive studies on hypoglycemia in type 1 patients apply also for type 2 diabetes. Recent reports indicate that type 2 diabetic patients of long duration react similarly to a hypoglycemic clamp as type 1 diabetic patients while well controlled type 2 diabetics had even more favorable thresholds for counter-regulatory hormone secretion. On the basis of these considerations the aims of this study are to 1) more precisely define the mechanisms of hypoglycemia in type 2 diabetes, 2) to investigate differences on glucose and lactate metabolism of bedtime NPH insulin versus glargine. To address these objectives we will use the hypoglycemic clamping technique combined with infusion of stable isotopes of glucose and lactate and non-invasive measurement of muscle flow characteristics at hypoglycemia.
BACKGROUND AND AIM: Patients with inflammatory bowel disease have an increased risk of developing colorectal cancer as compared with the general population. Endoscopic surveillance to detect early dysplastic changes is advised by several published clinical guidelines, which provide recommendations as to the timing and performance of surveillance procedures. There is a paucity of data as to adherence with these guidelines in clinical practice.
METHODS: A longitudinal inception cohort study of all new patients diagnosed with inflammatory bowel disease across a service network of Australian hospitals between January 2005 and June 2014, with continuous follow-up in a gastroenterology clinic until December 31, 2022. Patients were included if they warranted surveillance according to the Australian guidelines. Adherence to guidelines and technical and quality measures were reported.
RESULTS: A total of 136 patients were included, and a total of 263 surveillance procedures were performed. Ninety-five patients (70%) had their first surveillance colonoscopy within the correct time interval. Fifty patients (37%) were completely adherent to guidelines with respect to timing of all surveillance procedure. The overall dysplasia detection rate for surveillance procedures was 10%. Chromoendoscopy was only performed in 16% of procedures.
CONCLUSIONS: Adherence to endoscopic surveillance guidelines with regard to timing of procedures and the utilization of chromoendoscopy is poor. Further clinician education, promotion of the surveillance guidelines and incorporation of chromoendoscopy training as part of the national colonoscopy training program may improve adherence to guidelines.
Participants will receive GS-1427 Dose A Day 1 through Week 12 (Part 1A). Participants will be eligible to continue and remain on the same dose of GS-1427 through Week 52 (Part 1B).
LESCOL and LESCOL XL are contraindicated in women who are pregnant or may become pregnant. Serum cholesterol and triglycerides increase during normal pregnancy, and cholesterol or cholesterol derivatives are essential for fetal development. LESCOL and LESCOL XL may cause fetal harm when administered to pregnant women. Atherosclerosis is a chronic process and the discontinuation of lipid-lowering drugs during pregnancy should have little impact on the outcome of long-term therapy of primary hypercholesterolemia.

LESCOL and LESCOL XL should be administered to women of childbearing age only when such patients are highly unlikely to conceive and have been informed of the potential hazards If the patient becomes pregnant while taking this drug, LESCOL and LESCOL XL should be discontinued and the patient should be apprised of the potential hazard to the fetus [ ]. .see Use In Specific Populations (8.1)